PharmaEssentia Corporation (6446.TW) stock analysis

In our weekly check, PharmaEssentia Corporation is graded A (A to F). Of 24 checks on debt, profit, cash flow and trend: 21 pass, warnings: 1, red flags: 2.

About PharmaEssentia Corporation

PharmaEssentia Corporation is a Healthcare company (Drug Manufacturers - Specialty & Generic) based in Taiwan, listed on TAI as 6446.TW.

What our checks show for 6446.TW

Red flags

• The price swings a lot: 53% annual volatility. Expect large ups and downs.
• The stock has fallen as much as 76% from a peak. Would you have held through that?

Warning signs

• Analysts expect the net margin to shrink by 1.1 points from today's 36.8%.

Strengths

• Debt is low: 0.03x equity.
• Operating profit covers interest 363 times over.
• The net margin rose by 465 points over 5 years, to 36.8%.
• The gross margin is 89.8% and has risen by 47.5 points: pricing power is holding.
• Analysts expect earnings per share to grow about 61% a year over the next years.
• Analysts expect revenue to grow about 60.7% a year over the next years.

Next earnings report: 2026-11-11

Similar companies

LUPIN.NS · LAURUSLABS.NS · 3692.HK · 4523.T · TORNTPHARM.NS · DIVISLAB.NS

Questions

What grade does PharmaEssentia Corporation (6446.TW) have?

In our weekly check, PharmaEssentia Corporation is graded A (A to F). Of 24 checks on debt, profit, cash flow and trend: 21 pass, warnings: 1, red flags: 2. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of 6446.TW stock?

This week's biggest flags for PharmaEssentia Corporation: Very volatile, Deep past fall, Margins expected to shrink. In total 3 of 24 checks show a warning or a red flag.

What does PharmaEssentia Corporation do?

PharmaEssentia Corporation is a Healthcare company (Drug Manufacturers - Specialty & Generic) based in Taiwan, listed on TAI as 6446.TW.

When does PharmaEssentia Corporation report earnings next?

The next earnings report is expected on 2026-11-11. We re-run the checks every week, so the grade can change after it.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-10-24

Open the full analysis